Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE
    • Publication Information:
      Publication: New York Ny : Wiley-Liss
      Original Publication: New York, Liss.
    • Subject Terms:
      SARS-CoV-2* ; COVID-19*/diagnosis ; COVID-19*/epidemiology; Female ; Infant ; Humans ; Kenya/epidemiology ; Seroepidemiologic Studies ; Reproducibility of Results ; Enzyme-Linked Immunosorbent Assay/methods ; Nucleocapsid ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; Sensitivity and Specificity
    • Abstract:
      A multitude of enzyme-linked immunosorbent assays (ELISAs) has been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies since the coronavirus disease 2019 pandemic started in late 2019. Assessing the reliability of these assays in diverse global populations is critical. This study compares the use of the commercially available Platelia Total Ab Assay (Bio-Rad) nucleocapsid ELISA to the widely used Mount Sinai spike IgG ELISA in a Kenyan population seroprevalence study. Using longitudinal plasma specimens collected from a mother-infant cohort living in Nairobi, Kenya between May 2019 and December 2020, this study demonstrates that the two assays have a high qualitative agreement (92.7%) and strong correlation of antibody levels (R 2  = 0.973) in repeated measures. Within this cohort, seroprevalence detected by either ELISA closely resembled previously published seroprevalence estimates for Kenya during the sampling period and no significant difference in the incidence of SARS-CoV-2 antibody detection by either assay was observed. Assay comparability was not affected by HIV exposure status. These data support the use of the Platelia SARS-CoV-2 Total Ab ELISA as a suitable high-throughput method for seroprevalence studies in Kenya.
      (© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
    • References:
      Clin Transl Immunology. 2022 Jan 30;11(2):e1369. (PMID: 35127087)
      J Clin Microbiol. 2020 Sep 22;58(10):. (PMID: 32665420)
      Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876)
      Sci Immunol. 2020 May 19;5(47):. (PMID: 32430309)
      Nat Rev Microbiol. 2021 Mar;19(3):155-170. (PMID: 33116300)
      Science. 2020 Aug 14;369(6505):756-757. (PMID: 32792376)
      Science. 2021 Jan 1;371(6524):79-82. (PMID: 33177105)
      Clin Infect Dis. 2022 Jan 29;74(2):288-293. (PMID: 33893491)
      Elife. 2020 Apr 02;9:. (PMID: 32228860)
      Science. 2021 Nov 19;374(6570):989-994. (PMID: 34618602)
      J Clin Virol. 2020 Aug;129:104480. (PMID: 32505777)
      Lancet. 2022 Apr 16;399(10334):1513-1536. (PMID: 35279232)
      J Med Virol. 2021 Feb;93(2):803-811. (PMID: 32667733)
      Emerg Microbes Infect. 2020 Dec;9(1):382-385. (PMID: 32065055)
      iScience. 2021 Sep 24;24(9):102937. (PMID: 34368647)
      J Med Virol. 2023 Jan;95(1):e28221. (PMID: 36251533)
      J Clin Virol. 2020 Nov;132:104613. (PMID: 32942137)
      Clin Infect Dis. 2021 Dec 16;73(12):2366-2368. (PMID: 33693643)
      Clin Transl Immunology. 2021 Feb 28;10(3):e1258. (PMID: 33680466)
      Clin Infect Dis. 2020 Jul 28;71(15):778-785. (PMID: 32198501)
      Curr Protoc Microbiol. 2020 Jun;57(1):e100. (PMID: 32302069)
      Nat Commun. 2021 Jan 4;12(1):113. (PMID: 33397956)
      PLoS Med. 2006 Jul;3(7):e237. (PMID: 16796401)
      J Clin Virol. 2020 Aug;129:104544. (PMID: 32663788)
      Nat Commun. 2020 Jul 14;11(1):3581. (PMID: 32665645)
      Sci Transl Med. 2020 Sep 2;12(559):. (PMID: 32817357)
      Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. (PMID: 33400782)
      Open Forum Infect Dis. 2021 Jun 12;8(7):ofab314. (PMID: 34660838)
      Nature. 2021 Feb;590(7844):146-150. (PMID: 33142304)
      PLoS One. 2023 Jan 17;18(1):e0278675. (PMID: 36649247)
      Cell Rep Med. 2021 Jan 19;2(1):100189. (PMID: 33495758)
      PLoS One. 2022 Oct 14;17(10):e0265478. (PMID: 36240176)
      Nat Commun. 2020 Sep 1;11(1):4378. (PMID: 32873791)
      Int J Infect Dis. 2021 Nov;112:25-34. (PMID: 34481966)
    • Grant Information:
      Canada CIHR; R01 HD092311 United States HD NICHD NIH HHS; R00 DK107923 United States DK NIDDK NIH HHS; United States NH NIH HHS; R01 AI138709 United States AI NIAID NIH HHS; 202005 Canada CIHR; 201709 Canada CIHR
    • Contributed Indexing:
      Keywords: ELISA; Kenya; SARS-CoV-2; nucleocapsid; serology; spike
    • Accession Number:
      0 (Antibodies, Viral)
      0 (Spike Glycoprotein, Coronavirus)
      0 (spike protein, SARS-CoV-2)
    • Publication Date:
      Date Created: 20221017 Date Completed: 20230110 Latest Revision: 20230208
    • Publication Date:
      20240628
    • Accession Number:
      PMC9839577
    • Accession Number:
      10.1002/jmv.28221
    • Accession Number:
      36251533